Article
A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial
2021-04-15
Abstract excerpt
Background: The antibacterial, anti-inflammatory and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-moderate disease are lacking. We assessed whether azithromycin is effective in reducing hospitalisation in patients with mild-moderate COVID-19. <br><br>Methods: This open-label, randomised superiority clinical trial at 19 centres in the United Kingdom e...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c2bfb967-4a3a-5f45-bca4-d0e70a8fa7a6
- DOI
- 10.2139/ssrn.3827019
